Understand the source comparison
10 Peptides Researcher Should Know 2026: Feature Comparison
Survodutide GLP-1/GIP/Glucagon triple agonist ~160 hours Metabolic syndrome, obesity models 2–8°C refrigerated Most comprehensive metabolic modulator. Addresses insulin resistance, appetite, and hepatic fat oxidation simultaneously Mazdutide GLP-1/Glucagon dua
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Survodutide
- GLP-1/GIP/Glucagon triple agonist
- ~160 hours
- Metabolic syndrome, obesity models
- 2–8°C refrigerated
- Most comprehensive metabolic modulator. Addresses insulin resistance, appetite, and hepatic fat oxidation simultaneously
- Mazdutide
- GLP-1/Glucagon dual agonist
- ~120 hours
- Weight reduction, NAFLD models
- Strong glucagon component increases energy expenditure beyond GLP-1 monotherapy
- Dihexa
- HGF receptor agonist (BDNF upregulation)
- ~4 hours (CNS penetration sustained 8–12 hours)
- Neurodegeneration, cognitive decline
- −20°C frozen (pre-reconstitution)
- Structural neuroplasticity agent. Increases dendritic spine density, not just neurotransmitter activity
- Cerebrolysin
- Neurotrophic factor cocktail (BDNF, GDNF, NGF)
- ~8 hours
- Stroke recovery, TBI, neurodegenerative models
- Gold standard neuroprotective in acute injury models
- P21
- CNTF fragment (STAT3 pathway activation)
- ~6 hours
- Motor neuron preservation, memory consolidation
- 2–8°C refrigerated (use within 72 hours)
- Mitochondrial stabilizer under oxidative stress. Critical for ALS models
- Thymalin
- Thymic peptide (T-cell maturation)
- ~12 hours
- Immune senescence, post-chemo recovery
- Restores naive T-cell populations without broad immune activation
- KPV
- NF-κB inhibitor (anti-inflammatory)
- ~2 hours (local tissue concentration sustained 6–8 hours)
- IBD models, localized inflammation
- Tissue-specific inflammation control without systemic immunosuppression
- Cartalax
- Nrf2 activator (chondrocyte antioxidant)
- ~4 hours
- Osteoarthritis, cartilage repair
- Reduces oxidative damage in cartilage without NSAID side effects
- MK-677
- Ghrelin receptor agonist (GH secretagogue)
- ~24 hours
- Muscle wasting, bone density studies
- Room temperature stable (oral compound)
- Orally bioavailable GH secretagogue. Preserves endogenous GH pulsatility
- CJC-1295/Ipamorelin
- GHRH analog + ghrelin agonist
- ~144 hours (CJC-1295), ~2 hours (Ipamorelin)
- GH pulse optimization, recovery models
- Synergistic GH release. CJC amplifies pituitary sensitivity, Ipamorelin triggers pulse